{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:01:33Z","timestamp":1791003693513,"version":"4.1.0"},"reference-count":32,"publisher":"Japan Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1507\/endocrj.ej20-0222","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T22:10:12Z","timestamp":1593555012000},"page":"1127-1138","source":"Crossref","is-referenced-by-count":17,"title":["Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration"],"prefix":"10.1507","volume":"67","author":[{"given":"Masashi","family":"Isshiki","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Saitama Medical University Hospital, Saitama 350-0495, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Caress Sapporo Hokko Memorial Clinic, Hokkaido 065-0027, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Hayashino","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Tenri Hospital, Nara 632-8552, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sumita","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Japanese Red Cross Ogawa Hospital, Saitama 355-0397, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology and Metabolism, Jichi Medical University Saitama Medical Center, Saitama 330-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Kansai Medical University, Osaka 573-1191, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Shiojima","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Kansai Medical University, Osaka 573-1191, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Satoh-Asahara","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Kitazato","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Japanese Red Cross Omori Hospital, Tokyo 143-8527, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Saitama Medical University Hospital, Saitama 350-0495, Japan"},{"name":"Department of Endocrinology and Diabetes, Japanese Red Cross Ogawa Hospital, Saitama 355-0397, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigo","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Saitama Medical University Hospital, Saitama 350-0495, Japan"},{"name":"Department of Endocrinology and Diabetes, Japanese Red Cross Ogawa Hospital, Saitama 355-0397, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Saitama Medical University Hospital, Saitama 350-0495, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ikegami","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Saitama Medical University Hospital, Saitama 350-0495, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Saitama Medical University Hospital, Saitama 350-0495, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Saitama Medical University Hospital, Saitama 350-0495, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiko","family":"Noda","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Saitama Medical University Hospital, Saitama 350-0495, Japan"},{"name":"Department of Diabetes, Metabolism and Endocrinology, Ichikawa Hospital, International University of Health and Welfare, Chiba 272-0827, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, et al. (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117\u20132128.","DOI":"10.1056\/NEJMoa1504720"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, et al. (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644\u2013657.","DOI":"10.1056\/NEJMoa1611925"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, et al. (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380: 2295\u20132306.","DOI":"10.1056\/NEJMoa1811744"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 American Diabetes Association (2019) Standards of medical care in diabetes-2019 Abridged for Primary Care Providers. Clin Diabetes 37: 11\u201334.","DOI":"10.2337\/cd18-0105"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker <i>vs.<\/i> diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981\u20132997.","DOI":"10.1001\/jama.288.23.2981"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Kanaoka T, Tamura K, Wakui H, Ohsawa M, Azushima K, et al. (2013) L\/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease. Int J Mol Sci 14: 16866\u201316881.","DOI":"10.3390\/ijms140816866"},{"key":"7","unstructured":"7 Uzu T, Nakamura T, Ashida N, Togashi K (2016) Development and evaluation of EIA for the detection of plasma renin activity. Jpn J Med Pharm Sci 73: 311\u2013321 (In Japanese)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Struthers AD, MacDonald TM (2004) Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 61: 663\u2013670.","DOI":"10.1016\/j.cardiores.2003.11.037"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, et al. (1972) Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 286: 441\u2013449.","DOI":"10.1056\/NEJM197203022860901"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Parikh NI, Gona P, Larson MG, Wang TJ, Newton-Cheh C, et al. (2007) Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J 28: 2644\u20132652.","DOI":"10.1093\/eurheartj\/ehm399"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11 Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, et al. (2005) Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation 112: 110\u2013116.","DOI":"10.1161\/CIRCULATIONAHA.104.525527"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Meade TW, Cooper JA, Peart WS (1993) Plasma renin activity and ischemic heart disease. N Engl J Med 329: 616\u2013619.","DOI":"10.1056\/NEJM199308263290905"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709\u2013717.","DOI":"10.1056\/NEJM199909023411001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, et al. (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364: 11\u201321.","DOI":"10.1056\/NEJMoa1009492"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, et al. (2014) Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2: 944\u2013953.","DOI":"10.1016\/S2213-8587(14)70194-9"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Nagase M, Fujita T (2013) Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol 9: 86\u201398.","DOI":"10.1038\/nrneph.2012.282"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Bomback AS, Klemmer PJ (2007) The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3: 486\u2013492.","DOI":"10.1038\/ncpneph0575"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, et al. (2001) Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 37: 1808\u20131812.","DOI":"10.1016\/S0735-1097(01)01237-2"},{"key":"19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/hrt.82.1.57","volume":"82","author":"RJ MacFadyen","year":"1999","unstructured":"19 MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD (1999) How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82: 57\u201361.","journal-title":"Heart","ISSN":"https:\/\/id.crossref.org\/issn\/0007-0769","issn-type":"print"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20 Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH (2004) Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47: 1936\u20131939.","DOI":"10.1007\/s00125-004-1542-0"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A (1981) Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91: 457\u2013465.","DOI":"10.1677\/joe.0.0910457"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Sato A, Saruta T (2001) Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 29: 13\u201321.","DOI":"10.1177\/147323000102900103"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Cicoira M, Zanolla L, Franceschini L, Rossi A, Golia G, et al. (2002) Relation of aldosterone \u201cescape\u201d despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 89: 403\u2013407.","DOI":"10.1016\/S0002-9149(01)02261-5"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24 Sato A, Hayashi K, Naruse M, Saruta T (2003) Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41: 64\u201368.","DOI":"10.1161\/01.HYP.0000044937.95080.E9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Lijnen P, Fagard R, Staessen J, Amery A (1981) Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension. Br J Clin Pharmacol 12: 387\u2013392.","DOI":"10.1111\/j.1365-2125.1981.tb01231.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Takeuchi T, Dohi K, Omori T, Moriwaki K, Sato Y, et al. (2015) Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure. Int J Cardiol 201: 1\u20133.","DOI":"10.1016\/j.ijcard.2015.07.072"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Nomiyama T, Shimono D, Horikawa T, Fujimura Y, Ohsako T, et al. (2018) Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION). Endocr J 65: 859\u2013867.","DOI":"10.1507\/endocrj.EJ18-0022"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Yasui A, Lee G, Hirase T, Kaneko T, Kaspers S, et al. (2018) Empagliflozin induces transient diuresis without changing long-term overall fluid balance in Japanese patients with type 2 diabetes. Diabetes Ther 9: 863\u2013871.","DOI":"10.1007\/s13300-018-0385-5"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Iijima H, Kifuji T, Maruyama N, Inagaki N (2015) Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus. Adv Ther 32: 768\u2013782.","DOI":"10.1007\/s12325-015-0234-0"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, et al. (2009) Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med 15: 545\u2013552.","DOI":"10.1038\/nm.1960"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Karg MV, Bosch A, Kannenkeril D, Striepe K, Ott C, et al. (2018) SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol 17: 5.","DOI":"10.1186\/s12933-017-0654-z"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Verma S, McMurray JJV (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 61: 2108\u20132117.","DOI":"10.1007\/s00125-018-4670-7"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/11\/67_EJ20-0222\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T03:43:03Z","timestamp":1606534983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/11\/67_EJ20-0222\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej20-0222","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}